


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhongzhi Pharmaceutical Holdings Limited

中智藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3737)

SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION CONSTRUCTION CONTRACTS

Reference is made to the announcement of Zhongzhi Pharmaceutical Holdings Limited dated 24 March 2021 (the “**Announcement**”) in relation to the construction contracts. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise defined.

The Board wishes to provide additional information on the contractor. The contractor, Guangdong Zhengdong, is ultimately owned or controlled as to (i) 80% by Mr. Chen Jianping; and (ii) 20% by Ms. Lin Yongxi.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, Mr. Chen Jianping and Ms. Lin Yongxi are third parties independent of and not connected with the Company and its connected persons.

Save as disclosed above, all other information contained in the Announcement remains unchanged.

By order of the Board
**Zhongzhi Pharmaceutical Holdings
Limited**
Mr. Lai Zhi Tian
Chairman and Executive Director

Hong Kong, 7 April 2021

As at the date of this announcement, the Board comprises nine directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Cao Xiao Jun and Mr. Cheng Jin Le. The non-executive directors are Ms. Jiang Li Xia and Mr. Yang Ai Xing. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.